UK Urokinase, identified by the CAS number 9039 - 53 - 6, is a remarkable enzyme that plays a crucial role in the human body, particularly in its interaction with blood vessels. As a leading supplier of UK Urokinase CAS 9039 - 53 - 6, I am excited to delve into the intricate mechanisms of how this enzyme interacts with blood vessels and its implications in the medical field.
Structure and Basic Properties of UK Urokinase
UK Urokinase is a serine protease, which means it has a specific active site that can cleave peptide bonds in proteins. Structurally, it exists in two forms: low - molecular - weight urokinase (LMW - UK) and high - molecular - weight urokinase (HMW - UK). HMW - UK is the predominant form in the body and is converted to LMW - UK by proteolytic cleavage.
This enzyme is synthesized and secreted by various cells, including kidney cells. It has a high degree of specificity for its substrate, which is plasminogen. Plasminogen is an inactive precursor of plasmin, an enzyme that is essential for the breakdown of fibrin, the main component of blood clots.
Interaction with Blood Vessels: Fibrinolysis
One of the most significant ways UK Urokinase interacts with blood vessels is through the process of fibrinolysis. When a blood vessel is damaged, platelets aggregate at the site of injury, and fibrin is deposited to form a clot. This is a normal physiological response to prevent excessive bleeding. However, once the injury has healed, the clot needs to be removed to restore normal blood flow.
UK Urokinase binds to plasminogen and cleaves it at a specific peptide bond, converting it into plasmin. Plasmin then acts on fibrin, breaking it down into smaller fragments called fibrin degradation products. This process helps to dissolve the blood clot within the blood vessel. By promoting fibrinolysis, UK Urokinase can prevent the formation of occlusive blood clots that can lead to serious conditions such as deep vein thrombosis (DVT), pulmonary embolism, and myocardial infarction.
Receptor - Mediated Effects on Blood Vessel Cells
In addition to its role in fibrinolysis, UK Urokinase can also interact with specific receptors on the surface of blood vessel cells. The urokinase - type plasminogen activator receptor (uPAR) is expressed on the surface of endothelial cells, smooth muscle cells, and monocytes. When UK Urokinase binds to uPAR, it triggers a series of intracellular signaling pathways.
Binding of UK Urokinase to uPAR on endothelial cells can enhance the migration and proliferation of these cells. Endothelial cells line the inner surface of blood vessels, and their proper function is essential for maintaining the integrity of the blood vessel wall. By promoting endothelial cell migration and proliferation, UK Urokinase can contribute to the repair of damaged blood vessels.
On smooth muscle cells, UK Urokinase - uPAR interaction can affect their contractility and growth. In some cases, it may prevent excessive smooth muscle cell proliferation, which is associated with the development of atherosclerosis. Atherosclerosis is a condition characterized by the buildup of plaque in the blood vessels, leading to narrowing and hardening of the arteries.
Role in Inflammation and Immune Response
Blood vessels are also involved in the body's immune and inflammatory responses. UK Urokinase can modulate these responses within the context of blood vessels. During inflammation, immune cells such as monocytes and neutrophils are recruited to the site of injury or infection. These cells express uPAR, and UK Urokinase can interact with them.
When UK Urokinase binds to uPAR on immune cells, it can enhance their ability to migrate through the blood vessel wall and into the surrounding tissues. This is important for the proper functioning of the immune system, as immune cells need to reach the site of infection or injury to eliminate pathogens and initiate the healing process.
Clinical Applications and the Significance of Our Supply
The unique interactions of UK Urokinase with blood vessels have led to its extensive use in clinical medicine. It is commonly used as a thrombolytic agent to treat acute myocardial infarction, DVT, and pulmonary embolism. By dissolving blood clots, it can restore blood flow to vital organs and prevent tissue damage.
As a supplier of UK Urokinase CAS 9039 - 53 - 6, we ensure the high quality and purity of our product. Our UK Urokinase is produced using advanced biotechnological methods, which guarantee its safety and efficacy. We understand the critical role that this enzyme plays in the treatment of various cardiovascular and thromboembolic diseases, and we are committed to providing a reliable supply to pharmaceutical companies and research institutions around the world.
Comparison with Other Related Products
In the field of human APIs, there are other products that are also important in the medical field. For example, Carbetocin and Carbetocin API 37025 - 55 - 1 are used mainly in obstetrics to prevent postpartum hemorrhage. While UK Urokinase is focused on blood vessel - related conditions such as clot dissolution, Carbetocin is related to uterine contraction and hemostasis in the context of childbirth. Each product has its unique mechanism of action and application, but they all contribute to the overall well - being of patients.
Conclusion and Call to Action
In conclusion, UK Urokinase CAS 9039 - 53 - 6 is a fascinating enzyme with multiple ways of interacting with blood vessels. Its role in fibrinolysis, receptor - mediated effects on blood vessel cells, and modulation of inflammation and immune response makes it an essential therapeutic agent in the treatment of various vascular diseases.
If you are involved in pharmaceutical research, development, or production and are interested in our high - quality UK Urokinase, we invite you to contact us for procurement and further discussions. Our team of experts is ready to provide you with detailed information and support to meet your specific needs. You can explore more about our Urokinase 9039 - 53 - 6 on our website.
References
- Collen D. "Fibrinolysis and the control of hemostasis." Blood. 1999;93(10):3843 - 3860.
- Blasi F, Carmeliet P. "uPAR: a versatile signalling orchestrator." Nature Reviews Molecular Cell Biology. 2002;3(4):932 - 943.
- Sobel BE. "Urokinase - type plasminogen activator: a multifunctional vascular protein." Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21(11):1784 - 1792.
